If you have been reading about MC1R and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
These observations of discrete inheritance and the segregation of alleles are collectively known as Mendel's first law or the Law of Segregation. However, the probability of getting one gene over the other can change due to dominant, recessive, homozygous, or heterozygous genes. For example, Mendel found that if you cross heterozygous organisms your odds of getting the dominant trait is 3:1. Real geneticists study and calculate probabilities by using theoretical probabilities, empirical probabilities, the product rule, the sum rule, and more.
Libya had long supported the FROLINAT militia in neighbouring Chad, but FROLINAT became divided over its ties to Libya in 1976. In January 1978, the anti-Libya faction within FROLINAT, led by Hissène Habré, switched sides and allied with Chadian President Félix Malloum. Meanwhile, the pro-Libya faction within FROLINAT, led by Goukouni Oueddei, renamed itself People's Armed Forces (FAP). In December 1980, Gaddafi reinvaded Chad at the request of the FAP-controlled GUNT government to aid in the civil war; in January 1981, Gaddafi suggested a political merger. The Organisation of African Unity (OAU) rejected this and called for a Libyan withdrawal, which came in November 1981. The civil war resumed, and Libya sent troops back in. In 1982, the GUNT government was overthrown by Habré's forces and Oueddei fled to Libya, where Gaddafi provided him with arms to continue to guerrilla war against Habré. In November 1984, Gaddafi met with French President François Mitterrand; both agreed to withdraw from Chad. Oueddei broke with Gaddafi in 1985 due to the former's intentions to negotiate a truce with Habré. Consequently, he was placed under house arrest by Gaddafi and allegedly arrested by Libyan police and shot in the stomach. Oueddei survived the shooting and fled to Algeria, but continued to claim he and Gaddafi enjoyed a good relationship. When Gaddafi ordered the remnant of GUNT to attack Habré in February 1986 in violation of his agreement with Mitterrand, France launched Operation Épervier, which escalated into the Toyota War.
== Scientific contributions == Potassium channels demonstrate a seemingly counterintuitive activity: they permit the passage of potassium ions, whereas they do not allow the passage of the much smaller sodium ions. Before MacKinnon's work, the detailed molecular architecture of potassium channels and the means by which they conduct ions were only generally known and indirectly inferred. In 1998, despite barriers to the structural study of integral membrane proteins that had thwarted most attempts for decades, MacKinnon and colleagues determined the three-dimensional molecular structure of a potassium channel from an actinobacterium, Streptomyces lividans, utilizing X-ray crystallography. With this structure and other biochemical experiments, MacKinnon and colleagues were able to explain the exact mechanism by which potassium channel selectivity occurs. His prize-winning research was conducted primarily at the Cornell High Energy Synchrotron Source (CHESS) of Cornell University, and at the National Synchrotron Light Source (NSLS) of Brookhaven National Laboratory. MacKinnon was elected to the American Philosophical Society in 2005. In 2007 he became a foreign member of the Royal Netherlands Academy of Arts and Sciences.
=== Evidence in mammals === Publishing in Science in 1961, Julius Axelrod found an N-methyltransferase enzyme capable of mediating biotransformation of tryptamine into DMT in a rabbit's lung. This finding initiated a still ongoing scientific interest in endogenous DMT production in humans and other mammals. From then on, two major complementary lines of evidence have been investigated: Localization and further characterization of the N-methyltransferase enzyme, and analytical studies looking for endogenously-produced DMT in body fluids and tissues. In 2013, researchers reported DMT in the pineal gland microdialysate of rodents. A study published in 2014 reported the biosynthesis of N,N-dimethyltryptamine (DMT) in the human melanoma cell line SK-Mel-147 including details on its metabolism by peroxidases. It is assumed that more than half of the amount of DMT produced by the acidophilic cells of the pineal gland is secreted before and during death, the amount being 2.5–3.4 mg/kg. Contrarily, this claim by Strassman has been criticized by David Nichols who notes that DMT does not appear to be produced in any meaningful amount by the pineal gland. Removal or calcification of the pineal gland does not induce any of the symptoms caused by removal of DMT. The symptoms presented are consistent solely with reduction in melatonin, which is the pineal gland's known function. Nichols instead suggests that dynorphin and other endorphins are responsible for the reported euphoria experienced by patients during a near-death experience.
Falkenrath; Paul Taylor, director of chemical and biological defence at Porton Down; the National Domestic Preparedness Consortium in the US; General John Doesburg, of the Chemical & Biological Defense Command; Conor Egleston of Southampton General Hospital; on 10 April 1972 the Biological Weapons Convention was signed by the UK, the US and the Soviet Union, but the West suspected that the Soviet Union would still continue its research, which was proved when microbiologist Ken Alibek defected in 1992, who worked at the Stepnogorsk Scientific and Technical Institute for Microbiology in Kazakhstan; the Soviets had around 25,000 scientists on their bio-warfare programme in the 1980s; Eric Henchal of the United States Army Medical Research Institute of Infectious Diseases; the Iraqi biological weapons program had a site that made anthrax, which was discovered after Iraqi microbiologist Rihab Taha disclosed the vast scale of Iraqi manufacture of bioweapons; in 1998 Iraq blocked UN inspectors to its bioweapons plants, so the UK and the US bombed these plants; the USS Mitscher (DDG-57); the monkeypox virus; CODIS, the Combined DNA Index System, run by the FBI, which had allowed scientists to know if a criminal was black, white, Hispanic or native American, through genetic markers; microbiologist Ellen Vitetta of the University of Texas Southwestern Medical Center.
Sources: en.wikipedia.org
Simple branched alkanes often have a common name using a prefix to distinguish them from linear alkanes, for example n-butane, isobutane (or i-butane) for the two isomers of butane and n-pentane, isopentane, neopentane for the three isomers of pentane. IUPAC naming conventions can be used to produce a systematic name. The key steps in the naming of more complicated branched alkanes are as follows:
== Medical uses == Vinblastine is a component of a number of chemotherapy regimens, including ABVD for Hodgkin lymphoma, and along with methotrexate in the treatment of aggressive fibromatosis (desmoid tumor). It is also used to treat histiocytosis according to the established protocols of the Histiocytosis Association.
==== 2023–24 UEFA Women's Nations League B ==== 23 September – Ireland 3–0 Northern Ireland. 26 September – Hungary 0–4 Ireland. 27 October – Ireland 5–1 Albania. 31 October – Albania 0–1 Ireland. 1 December – Ireland 1–0 Hungary. 5 December – Northern Ireland 1–6 Ireland.
== Biology, medicine and chemistry == Code C08 Calcium channel blockers, in ATC (Anatomical Therapeutic Chemical Classification System) C08, Malignant neoplasm of other and unspecified major salivary glands ICD-10 code C8 complex, three proteins involved in the complement system (part of the immune system) Cervical spinal nerve 8 in human anatomy Carbon-8 (C-8 or 8C), an isotope of carbon An octyl-type hydrocarbon with eight carbon atoms like in a C8 bonded silica stationary phase column, a type of column used in reversed-phase chromatography Perfluorooctanoic acid (PFOA, known colloquially as C8), a ubiquitous chemical used in the production of PTFE
Sources: en.wikipedia.org
Br2 + H2O ⇌ HOBr + H+ + Br− (Kac = 7.2 × 10−9 mol2 dm−6) Br2 + 2 OH− ⇌ OBr− + H2O + Br− (Kalk = 2 × 108) Hypobromous acid is unstable to disproportionation. The hypobromite ions thus formed disproportionate readily to give bromide and bromate:
However, the quadroma method relies on random chance to form usable BsAb, and can be inefficient. Another method for manufacturing IgG-like BsAb is called "knobs into holes," and relies on introducing a mutation for a large amino acid in the heavy chain from one mAb, and a mutation for a small amino acid in the other mAb's heavy chain. This allows the target heavy chains (and their corresponding light chains) to fit together better, and makes the production of BsAbs more reliable.
Patients who do not drink may require fluids by nasogastric tube. Intravenous fluids are recommended only in those who have significant dehydration due to their potential complications, including congestive heart failure.
The four substrates of this enzyme are 6-hydroxynicotinic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are 2,5-dihydroxypyridine, oxidised NAD+, water, and carbon dioxide. It is a flavoprotein that uses flavin adenine dinucleotide as a cofactor.
=== Resistance === Resistance to colistin is rare, but has been described. As of 2017, no agreement exists about how to define colistin resistance. The Société Française de Microbiologie uses a MIC cut-off of 2 mg/L, whereas the British Society for Antimicrobial Chemotherapy sets a MIC cutoff of 4 mg/L or less as sensitive, and 8 mg/L or more as resistant. No standards for describing colistin sensitivity are given in the United States. The first known colistin-resistance gene in a plasmid which can be transferred between bacterial strains is mcr-1. It was found in 2011 in China on a pig farm where colistin is routinely used and became publicly known in November 2015. The presence of this plasmid-borne gene was confirmed starting December 2015 in South-East Asia, several European countries, and the United States. It is found in certain strains of the bacteria Paenibacillus polymyxa. India reported the first detailed colistin-resistance study, which mapped 13 colistin-resistant infections recorded over 18 months. It concluded that pan-drug-resistant infections, particularly those in the bloodstream, have a higher mortality. Multiple other cases were reported from other Indian hospitals. Although resistance to polymyxins is generally less than 10%, it is more frequent in the Mediterranean and South-East Asia (Korea and Singapore), where colistin resistance rates are increasing. Colistin-resistant E. coli was identified in the United States in May 2016. Multiple mobile colistin resistance (mcr) genes have been identified since the discovery of mcr-1.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.